UPDATE: 12 January 2012
Another report is out today linking statin drugs and diabetes. Natural Health News has been reporting on statins since 2006 and we have been covering the drugs in our other venues since 1996.
Numerous articles on this topic can be located on Natural Health News using our search function on the main page.
Here is a related report
30 March 2011 -
28 March -
Need I say more? Now more studies shoe increased risk of diabetes among other health problems from statins. And the cookie cutter medicine machine wants YOU to take this drug if you have diabetes. Its doing the same as aspartame. Red Yeast Rice is a statin and will have this effect in some people.
Another report is out today linking statin drugs and diabetes. Natural Health News has been reporting on statins since 2006 and we have been covering the drugs in our other venues since 1996.
Numerous articles on this topic can be located on Natural Health News using our search function on the main page.
Here is a related report
30 March 2011 -
People with Diabetes (PWD) are 70% more likely to have liver disease.
Diabetes Diary: This is now in process of publication, pre publication copies are $8, available from us.
Diabetes increases Parkinson's risk http://care.diabetesjournals.org/cgi/content/long/34/4/910I hope you are connecting the dots...
28 March -
Need I say more? Now more studies shoe increased risk of diabetes among other health problems from statins. And the cookie cutter medicine machine wants YOU to take this drug if you have diabetes. Its doing the same as aspartame. Red Yeast Rice is a statin and will have this effect in some people.
We offer a very good supplement to help raise HDL, lower LDL and reduce total cholesterol while decreasing triglycerides.
CLINICAL RESEARCH: LIPID-LOWERING AND DIABETES
CLINICAL RESEARCH: LIPID-LOWERING AND DIABETES
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Results From 3 Large Randomized Clinical Trials
David D. Waters, MD ,Jennifer E. Ho, MD ,David A. DeMicco, DPharm ,Andrei Breazna, PhD ,Benoit J. Arsenault, PhD ,Chuan-Chuan Wun, PhD ,John J. Kastelein, MD, PhD ,Helen Colhoun, MD, PhD andPhilip Barter, MD, PhD Division of Cardiology, San Francisco General Hospital, and the University of California at San Francisco, San Francisco, California
Pfizer, Inc., New York, New York
Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Public Health, University of Dundee, Dundee, Scotland
Heart Research Institute, Sydney, Australia
Manuscript received July 28, 2010; revised manuscript received October 4, 2010, accepted October 11, 2010.
* Reprint requests and correspondence: Dr. David D. Waters, Division of Cardiology, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, California 94114 (Email:dwaters@medsfgh.ucsf.edu).
Objectives: We sought to examine the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin.
Background: Statin therapy might modestly increase the risk of new-onset T2DM.
Methods: We used a standard definition of diabetes and excluded patients with prevalent diabetes at baseline. We identified baseline predictors of new-onset T2DM and compared the event rates inpatients with and without new-onset T2DM.
Results: In the TNT (Treating to New Targets) trial, 351 of 3,798 patients randomized to 80 mg of atorvastatin and 308 of 3,797 randomized to 10 mg developed new-onset T2DM (9.24% vs. 8.11%, adjusted hazard ratio [HR]: 1.10, 95% confidence interval [CI]: 0.94 to 1.29, p = 0.226). In the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial, 239 of 3,737 patients randomized to atorvastatin 80 mg/day and 208 of 3,724 patients randomized to simvastatin 20 mg/day developed new-onset T2DM (6.40% vs. 5.59%, adjusted HR: 1.19, 95% CI: 0.98 to 1.43, p = 0.072). In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, new-onset T2DM developed in 166 of 1,905 patients randomized to atorvastatin 80 mg/day and in 115 of 1,898 patients in the placebo group (8.71% vs. 6.06%, adjusted HR: 1.37, 95% CI: 1.08 to 1.75, p = 0.011). In each of the 3 trials, baseline fasting blood glucose, body mass index, hypertension, and fasting triglycerides were independent predictors of new-onset T2DM. Across the 3 trials, major cardiovascular events occurred in 11.3% of patients with and 10.8% of patients without new-onset T2DM (adjusted HR: 1.02, 95% CI: 0.77 to 1.35, p = 0.69).
Conclusions: High-dose atorvastatin treatment compared with placebo in the SPARCL trial is associated with a slightly increased risk of new-onset T2DM. Baseline fasting glucose level and features of the metabolic syndrome are predictive of new-onset T2DM across the 3 trials.
SOURCE: http://content.onlinejacc.org/misc/terms.dtl
Most read statin articles from 30+ on Natural Health News
Nov 21, 2010
More than 6 millions adults are prescribed statins by their GPs will be told about five new 'undesirable effects' in leaflets issued with packets of the drugs. These include sleep disturbances, memory loss, sexual dysfunction, . ...
Nov 14, 2008
It's been going this way for a while: even healthy people should be on the cholesterol-reducing drugs known as statins. That, in a nutshell, is the verdict of a study published over the weekend which found that even in people deemed to ...
Feb 04, 2008
No study has shown a significant reduction in mortality in women treated with statins. The University of British Columbia Therapeutics Initiative came to the same conclusion, with the finding that statins offer no benefit to women for ...
Jul 07, 2010
Statins for children 10 to 17 have been FDA approved since 2002. Now Pfizer seeks EU authorization. READ IT HERE FIRST: THE IMPORTANT ISSUES FACING YOU IN HEALTH CARE AT NATURAL HEALTH NEWS DAYS, AND OFTEN WEEKS OR MONTHS, ...
No comments:
Post a Comment